Novavax Inc. (Nasdaq: NVAX) will work with the National Institutes of Health to evaluate a virus-like particle vaccine against the swine flu, influenza A (H1N1), virus. Shares of the biopharmaceutical jumped $1.00 to $2.87.
Novavax To Evaluate Swine Flu Vaccine
June 04, 2009 at 13:23 PM EDT